Flex Pharma initiates human efficacy study with single molecule tablet in nocturnal leg cramps
Single molecule TRP ion channel agonist in randomized, blinded, controlled, cross-over study.
Flex Pharma has initiated a human proof-of-concept efficacy study in nocturnal leg cramps (NLC) with its chemically synthesized, single molecule, transient receptor potential (TRP) ion channel activator, formulated as an orally disintegrating tablet. The randomized, blinded, controlled, cross-over study is designed to evaluate the safety and efficacy of its single agent in over 50 subjects who suffer from nocturnal leg cramps on a frequent basis.
Nocturnal leg cramps can cause severe pain, interrupted sleep, reduced quality of life and interference with activities of daily living. The company estimates that NLC affects over four million Americans nightly; there is no approved therapeutic in the US to treat this condition.
“Based upon the statistically significant positive results from our recently completed human efficacy study in NLC with our proprietary extract formulation, we moved rapidly to initiate this NLC study with our single molecule TRP activator and we expect to soon begin Phase II studies with this agent in MS and ALS,” said Flex Pharma Chief Medical Officer Thomas Wessel, who served as the medical lead for three products approved in US: Razadyne, Lunesta and Ampyra. The company's studies of this agent in MS and ALS will be conducted outside the US.
“Flex Pharma is at the forefront of clinical development in NLC and the statistically significant human efficacy data generated in the prior NLC study are highly encouraging,” noted John Winkelman, Chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital and Flex Pharma Scientific Advisory Board member. “I am hopeful that Flex Pharma’s efforts will ultimately help the millions of people who suffer from this painful condition and currently have no safe and effective therapeutic options.”
“The recently completed study results support using the approach of specific TRP ion channel activation to reduce nocturnal leg cramps via Chemical Neuro Stimulation,” stated Bruce Bean, Harvard Medical School Professor of Neurophysiology and Flex Pharma Co-founder and Scientific Advisory Board Co-Chair. “These upcoming studies in multiple indications may help confirm the role of Chemical Neuro Stimulation as the general strategy to reduce alpha-motor neuron hyperexcitability for a broad range of neuromuscular conditions associated with cramps, spasms and possibly spasticity.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance